MarketMoodz
MoonLake Lead Drug Delivers Durable HS Response; FDA Filing On Track
MoonLake Immunotherapeutics reported durable lesion control through Week 40 in its VELA-1 and VELA-2 Phase 3 trials of sonelokimab for hidradenitis suppurativa. The company also reaffirmed a 52-week data readout in Q2 2026 and a BLA submission on track for H2 2026, as it weighs an FDA filing later in 2026. FDA feedback in January suggested substantial evidence of effectiveness could be established without another trial, contingent on VELA-2 safety.
Key Takeaways
- Durable lesion control through Week 40 across VELA-1/VELA-2 HS trials (sonelokimab)
- 52-week data expected in Q2 2026 and BLA submission on track for H2 2026
- FDA Type B briefing indicated substantial evidence could be established without new trials, pending VELA-2 safety
- S-OLARIS Phase 2 in axial spondyloarthritis showed an 81% response at Week 12 (contextual signal)
People Involved
- No specific individuals mentioned
Entities Involved
- MoonLake Immunotherapeutics (MLTX)Biotech company developing sonelokimab for hidradenitis suppurativa
- American Academy of Dermatology (AAD)Professional society hosting the 2026 Annual Meeting where data were presented
- U.S. Food and Drug Administration (FDA)Regulatory agency guiding potential approval pathway for SLK in HS
MarketMoodz Analysis
MoonLake’s Phase 3 data, if borne out in the 52-week readout, could clear a near-term regulatory path for SLK in hidradenitis suppurativa. Investors should watch the Q2 2026 data cadence and any safety signals from VELA-2 that could influence the FDA’s assessment of substantial evidence of effectiveness.
Historically, HS therapies have faced meaningful hurdles to prove durable lesion control and quality-of-life gains. MoonLake’s approach—aiming for a shorter, patient-friendly pathway to a BLA—follows a pattern seen in earlier biotech programs that balanced efficacy signals with safety guardrails. The company’s S-OLARIS signal in axial spondyloarthritis also adds optionality, though it operates in a separate indication with its own regulatory timeline.
What to watch next: the 52-week readout in Q2 2026, the VELA-2 safety data package, and the potential BLA submission in H2 2026. Also monitor updates from the S-OLARIS program and any new AAD 2026 disclosures that could refine the HS program’s risk/return profile.
Source: Original Article